Yilmaz, SezaiKayaalp, CuneytAra, CengizYilmaz, MehmetIsik, BurakAydin, CemalettinOzgor, Dincer2024-08-042024-08-0420130172-6390https://doi.org/10.5754/hge11290https://hdl.handle.net/11616/96238Background/Aims: Living donor liver transplantations (LDLT) is a definitive treatment for patients with end-stage liver disease (ESLD), especially in the countries with donation problem. Between April 2007 and April 2010, we performed LDLT in 289 patients. Fifteen of the cases required re-transplantations. This study evaluates these 304 consecutive LDLTs donor and recipient outcomes. Methodology: Complication rates and survival data of the recipients and donors of 304 LDLT cases were analyzed. Results: All donors are alive and well. Overall complication rate was 27%. Early postoperative recipient complication rate was 51%. Most frequent complication was infection. In the long-term there were 57 biliary stricture and 5 chronic bile fistula cases. Chronic and acute rejection attacks developed in 7 and 103 patients, respectively. Hepatic artery thrombosis rate was 8%. One, two and three year survival rates were 82%, 79% and 75%, respectively. Recipient mortality was 25%, mostly due to vascular complications, septic complications, liver dysfunction and chronic rejection. Conclusions: More than 150 liver tranplantations per year in a single center is a challenge in Turkey, where there is a shortage of deceased donor grafts. LDLT is a safe procedure for donors and effective for ESLD. Improvement in surgical technique would provide better outcomes.eninfo:eu-repo/semantics/closedAccessLiving-donor liver transplantationArticle60125110511092347814510.5754/hge112902-s2.0-84885801911N/AWOS:000330327700030Q3